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Abstract
When making funding decisions, research organisations largely consider the merits (e.g. scientific rigour and feasibility) 
of submitted research proposals; yet, there is often little or no reference to their value for money. This may be attributed to 
the challenges of assessing and integrating value of research into existing research prioritisation processes. We propose a 
framework that considers both the merits of research and its value for money to guide health research funding decisions. A 
practical framework is developed based on current processes followed by funding organizations for assessing investigator-
initiated research proposals, and analytical methods for evaluating the expected value of research. We apply the analytical 
methods to estimate the expected return on investment of two real-world grant applications. The framework comprises four 
sequential steps: (1) initial screening of applications for eligibility and completeness; (2) merit assessment of eligible pro-
posals; (3) estimating the expected value of research for the shortlisted proposals that pass the first two steps and ranking of 
proposals based on return on investment; and (4) selecting research proposals for funding. We demonstrate how the expected 
value for money can be efficiently estimated using certain information provided in funding applications. The proposed 
framework integrates value-for-money assessment into the existing research prioritisation processes. Considering value for 
money to inform research funding decisions is vital to achieve efficient utilisation of research budgets and maximise returns 
on research investments.
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1  Background
Health research is essential to improve individual and popu-
lation health by guiding decision making at the clinical and 
policy levels. Therefore, governments and research organi-
sations allocate considerable resources to support clinical 
trials and other research studies. For instance, the Austral-
ian Government established the Medical Research Future 
Fund (MRFF) with a total budget of $20 billion (all values 
are given in Australian dollars) to drive innovation, improve 
delivery of healthcare, and enhance the efficiency and effec-
tiveness of the health system in Australia [1]. However, 
research budgets are usually insufficient to fund all wor-
thy applications, and funding organisations must therefore 
make decisions about the best way to prioritise and select 
competing research proposals. These decisions are usually 
made based on the assessments of the merits (e.g. scientific 
rigour and feasibility) of the submitted research proposals, 
as judged by expert panels [2, 3], with little or no reference 
to explicit estimates of the value for money of proposed 
research programs [3]. Nevertheless, consideration of the 
expected costs and benefits of research proposals is funda-
mental to achieve efficient utilisation of research budgets and 
maximise returns on research investments.
Analytic approaches have been proposed to quantify the 
value of evaluative research (i.e., clinical trials and cohort 
studies) [3, 4]. The underlying principle of these approaches 
is to estimate the expected benefits of research for improving 
health outcomes (e.g. survival or quality of life), which can 
be expressed in monetary terms using a willingness-to-pay 
value for an additional unit of health outcome (e.g. $50,000 
per life-year gained). This expected benefit is compared to 
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Key Points for Decision Makers 
Research organisations must make decisions about the 
best way to prioritise and select competing research pro-
posals for funding. These decisions are often informed 
by the qualitative merits of research proposals.
Consideration of the expected costs and benefits of 
research proposals (i.e., value for money) is fundamental 
to achieve efficient utilisation of research budgets and 
maximise returns on research investments.
We propose a framework that considers both the merits 
of research and its value for money to guide health 
research funding decisions.
received and screened for eligibility, assessed and scored 
against predefined criteria, ranked, and finally selected based 
on discussions among the review panel members [3, 8–10]. 
This information is complemented by best international 
practices for research prioritisation methods and criteria 
reported in the literature [11–13]. The value-for-money 
component was based on the value of information-analysis 
approach [6, 7, 14–17], and value of improved implementa-
tion [18–22], whereby the expected benefits of a research 
study are explicitly compared with its expected costs.
A framework for prioritising research proposals for fund-
ing is presented in Fig. 1. The framework comprises four 
steps: (1) initial screening of applications; (2) assessment 
of research proposals’ merits; (3) estimating the value for 
money of research proposals; and (4) selecting research pro-
posals for funding.
2.1  Initial Screening
The first step after receiving applications for funding 
involves screening proposals for eligibility and complete-
ness. This step is done by administrators to verify that sub-
mitted proposals meet the eligibility criteria of the funding 
scheme and that all necessary information is provided in the 
submitted applications. Certain criteria can be applied at this 
stage such as relevance to the grant scheme, completeness 
of information and conformity to application guidelines. At 
this stage, ineligible or incomplete proposals are eliminated.
2.2  Assessment of Proposals’ Merits
The merits of the submitted research proposals are assessed 
using a predefined set of criteria (i.e., attributes). The 
selected criteria should represent the merits that stake-
holders believe should be present in the proposed research 
study. Relevant criteria can be identified in a number of 
ways including literature reviews, focus groups or surveys. 
In general, selection criteria can be grouped into representa-
tive domains such as relevance (i.e., why should we do it?, 
including the burden of disease, equity considerations and 
knowledge gap), appropriateness (i.e., should we do it?, 
including scientific rigour and suitability of methods), sig-
nificance of research outcomes (i.e., what will we get out 
of it?, including impact, capacity building and innovation), 
feasibility (i.e., can we do it?, including team quality and 
research environment) [11, 13]. Importantly, the chosen cri-
teria should be clear and well defined as well as being inde-
pendent of each other and non-redundant to avoid double 
counting [11, 13, 23]. The way the proposals are assessed 
against these criteria may vary according to the organiza-
tion’s processes and available resources. Applications can be 
shortlisted by excluding proposals that fail to meet any of the 
pre-specified criteria. Alternatively, submitted proposals can 
the expected costs of conducting the proposed research to 
inform if this research proposal is cost-effective. Unfortu-
nately, the application of quantitative approaches to priori-
tise research funding decisions in practice is limited [5, 6]. 
This may be attributed to two main reasons. First, the burden 
associated with quantitative approaches in terms of the avail-
ability of the technical skills within funding organisations 
and the additional time required to conduct the analyses [6, 
7]; notably, the peer-review process for the National Health 
and Medical Research Council (NHMRC) Project Grant 
scheme in 2017 took approximately 6 months to evaluate 
3500 applications [2]. Second, it is unclear how to incorpo-
rate the value-for-money criterion into the existing prioriti-
sation process alongside other attributes (i.e., criteria) such 
as research scientific rigor and team quality and capability.
The aim of this paper was to propose a practical frame-
work that considers both the merits of research and value 
for money to guide health research funding decisions by 
organisations in Australia. We describe, in some detail, how 
to quantify the value for money for assessing grant applica-
tions, and then provide two worked examples.
2  The Framework
In order to incorporate value for money into existing pro-
cesses for research prioritisation in Australia, the framework 
is informed by: (1) current processes by Australian funding 
organisations for assessing investigator-initiated research 
proposals, (2) international approaches and good practices 
for research prioritisation, and (3) common principles for 
evaluating value for money of research studies. The cur-
rent practices by Australian funding organisations are based 
on the peer-review principles for NHMRC grants and other 
major funding schemes listed on the Australian Competitive 
Grants Register [3, 8–10]. Typically, submitted proposals are 
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be assessed and scored against these criteria with each crite-
rion, or group of criteria, being assigned a weight reflecting 
its relative importance. This can be done using a structured 
and explicit approach such as multiple criteria decision anal-
ysis (MCDA) [23–25]. At the end of this step, a short list of 
proposals that have the required merits will move to the next 
step. To avoid double counting in research-value assessment, 
the scores from this step are not carried forward to the next 
step where the shortlisted proposals will be evaluated for 
their value for money.
2.3  Value for Money
In this stage, the expected value (i.e., benefits) of each short-
listed proposal is estimated. In estimating the additional 
value of a new research study, the expected benefits of two 
states are compared: (1) a factual state in which research 
takes place, and (2) a counterfactual state, in which research 
is not conducted [4].
Research informs decision making in two ways. First, col-
lecting more information may reduce the chance of making 
misguided decisions when the existing evidence is uncertain 
[12, 13]. Misguided decisions may lead to healthcare costs 
such as wasting resources on ineffective or unsafe inter-
ventions. Reducing uncertainty by collecting additional 
evidence better informs decision making, and in doing so 
avoids the costly consequences of suboptimal decisions 
[15, 17]. Second, research may influence the implementa-
tion of interventions (e.g. changing practice) by adding to 
information and evidence. Collecting further evidence has 
the potential to improve health outcomes by encouraging the 
implementation of the most effective and/or cost-effective 
intervention [18–20, 22, 26]. Thus, the expected value of a 
research study is the sum of its expected value in reducing 
decision uncertainty and its expected value in improving 
implementation [18].
These expected research benefits are scaled up by consid-
ering the population expected to benefit from research find-
ings and the evidence durability (i.e., the time over which 
evidence is useful). Then, the expected value of research at 
the population level is compared to the expected research 
costs to estimate the return on investment of each proposal.
2.3.1  Value of Research in Reducing Decision Uncertainty
Under budget constraints, the decision to adopt a new inter-
vention (i.e., to translate or implement the intervention) is 
typically guided by its ability to provide value for money 
(i.e., cost-effectiveness). Specifically, the costs and benefits 
of the new intervention are compared with the costs and ben-
efits of alternative options. The additional benefit of the new 
intervention can be converted to dollar value by multiplying 
the expected improvement in health by a monetary value 
per unit of health gained (e.g. $50,000 per life-year gained). 
Nevertheless, any evidence is never certain because we do 
not know the true values of effectiveness and cost estimates, 
and thus any decision based on this evidence is also uncer-
tain [27]. Under this uncertainty, making the wrong decision 
Fig. 1  Framework for prior-
itising research proposals for 
funding
Author's personal copy
 H. W. Tuffaha et al.
could lead to costly consequences to the healthcare system 
(i.e., the opportunity cost of adopting a suboptimal option). 
Thus, information is valuable because it reduces the risk of 
making wrong decisions.
Value of Information (VOI) analysis is a method to esti-
mate the expected costs of decision uncertainty, and, there-
fore, the value of research aimed at reducing this uncertainty. 
In estimating the cost of decision uncertainty, VOI considers 
two factors: (1) the probability of making the wrong decision 
(e.g. the probability the intervention is not cost-effective), 
and (2) the consequences of this error (e.g. opportunity loss 
of adopting a suboptimal intervention) [7, 15, 28]. If we 
had perfect information, we would avoid the cost of uncer-
tainty and maximise the expected monetary benefit of our 
decision. The difference between the expected benefit of a 
decision based on perfect information (i.e., no uncertainty) 
and the benefit made based on available evidence (i.e., with 
uncertainty) is the Expected Value of Perfect Information 
(EVPI) [29]. The EVPI is the value of the additional infor-
mation that would resolve all uncertainty; however, it is 
almost impossible in practice to have perfect information; 
and hence, what the EVPI represents is the maximum value 
(i.e., the upper-bound) of research benefit. The Expected 
Value of Sample Information (EVSI), on the other hand, esti-
mates the value of a clinical trial of a given sample size in 
reducing, but not resolving, decision uncertainty, which can 
be calculated as the difference between the expected benefit 
from a future clinical trial and the benefit based on current 
evidence [15]. Clearly, the data collected from additional 
research is not known at this stage but could be predicted by 
simulation [30, 31].
Typically, VOI requires the development of a decision-
analytic model to assess the cost-effectiveness and char-
acterise decision uncertainty; however, research funding 
organisations may not have the time and/or capacity to build 
models to evaluate all research proposals. A rapid approach 
is to use the minimal modelling for VOI calculation as sug-
gested by Meltzer et al. [32]. This approach can be per-
formed when the outcomes (and costs) of interest and the 
uncertainty around these estimates are sufficiently reported 
in prior evidence to inform a decision about the benefits of 
alternative interventions; for example, when a prior study 
captures comprehensive outcomes such as improvement in 
survival or quality-adjusted life-years (QALYs) gained. Even 
when intermediate outcomes are reported (e.g. progression-
free survival), these can be extrapolated using external data 
to obtain comprehensive measure of outcome [32, 33].
To calculate the expected value of reducing uncertainty, 
grant applications should provide the following information 
based on current evidence: the primary outcome(s) of the 
intended research, description of existing evidence includ-
ing type (e.g. pilot study, meta-analysis, or expert opinion) 
and sample size, the effectiveness of the comparator (e.g. 
baseline risk), relative effectiveness of the intervention 
(e.g. relative risk, risk difference), the estimated costs of 
the intervention and comparator, uncertainty around effec-
tiveness and cost estimates (e.g. standard error or confidence 
interval), willingness-to-pay for an additional unit of effec-
tiveness (e.g. per QALY gained or event avoided), and the 
sample size and follow-up duration of the new clinical trial. 
Table 1 summarises the information required in funding 
applications.
2.3.2  Value of Research in Improving Implementation
Based on existing evidence, there is a current level of 
uptake (i.e., implementation) of the interventions being 
researched; this can range from 0 (no implementation) to 
1 (perfect implementation). Perfect implementation cannot 
be achieved in practice; however, the results of new research 
can optimise the uptake of these interventions, leading to 
the implementation of the cost-effective intervention and 
disinvestment in interventions that do not provide value for 
money. Of course, there are other ways to optimise imple-
mentation other than research (e.g. knowledge transfer and 
incentives), but what we are interested in is the expected 
change in implementation that can be attributed to the 
results of new research [18, 20]. Thus, the value of research 
in changing the level of implementation is the difference 
between the expected benefits of the intervention from an 
improved level of implementation and the benefits based 
on current uptake levels [18, 20]. For this calculation, the 
applications should provide the current level of uptake of 
the researched interventions and the expected level of uptake 
when the new research results are out. The expected level 
of uptake in the future can be obtained from elicitation of 
expert belief conditional on the strength of evidence, realisti-
cally varying implementation levels over time to allow for 
evidence diffusion [18, 20].
2.3.3  Expected Value of Research at the Population Level
The expected value of research is the sum of the expected 
value of reducing uncertainty and the expected value of 
improving implementation [18]. This value is per patient; 
however, to calculate total research value at the population 
level, the expected value of research is multiplied by the 
population expected to benefit from the intervention over 
a given number of years. This duration should reflect the 
time over which the results from this research remain use-
ful. Because these benefits happen in the future, expected 
benefits are discounted at an appropriate discount rate (e.g. 
annual rate of 5%). The application should provide data 
on the incidence and/or prevalence population, depend-
ing on the nature of the condition being addressed (i.e., 
chronic or acute) as well as the number of years over which 
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the intervention is expected to remain useful in practice. 
Although a time horizon between 5 and 10 years is com-
monly used in the literature, better estimation of the time for 
the intervention to remain useful can be based on empirical 
evidence (e.g. historical data) or elicited from experts [14].
2.3.4  Research Cost–Benefit Comparison
Total research cost has two components, one financial (i.e., 
direct costs) and the other reflecting opportunity loss [20]. 
Direct costs comprise the fixed costs of setting up a trial, 
and variable costs, which is the cost per patient. Direct 
costs of research are obtained from the estimated budget in 
the grant application. The opportunity cost component is 
incurred by patients allocated to the control arm who will 
not benefit from the new intervention [26, 34]. The expected 
value of research at the population level is compared to the 
expected total research cost, the difference is the expected 
monetary gain of research. If the net gain is positive, then 
this proposed research study is cost-effective [20, 35, 36]. 
The return on investment is the expected net gain divided by 
the research cost. Proposals that are not cost-effective may 
be excluded and the rest of the proposals may be ranked 
according to their returns on investment. Grant applications 
should provide the expected research budget and the dura-
tion of the trial until the results are available.
2.4  Selecting Proposals for Funding
The final step in the framework involves the discussion and 
deliberation among panel members to reach consensus on 
which applications to fund. At this stage of the research 
prioritisation process, a short list of high-quality and cost-
effective proposals is considered. In making the final funding 
decisions, panel members will take into consideration both 
the merits and return-on-investment of competing propos-
als together with any other considerations (e.g. total budget 
available or equity). For instance, the panel may decide to 
fund applications with the highest return-on-investment and 
until the allocated budget is consumed. The final decision 
will be approved by the final decision maker (e.g. Minister 
of Health).
3  Examples of Value‑of‑Research 
Calculations
Two examples are presented to illustrate expected value-of-
research calculation for two funding proposals: (1) a ran-
domised controlled trial of a nurse-led multimodal inter-
vention for meeting the psychosocial care needs of men 
with advanced prostate cancer, and (2) a randomised con-
trolled trial of negative pressure wound therapy (NPWT) in 
Table 1  Summary of the information required to calculate expected value of research
Domains Inputs Clarifying statements
Value of resolving uncertainty Primary outcome(s) of the new research The primary outcome in the research proposal (e.g. survival, 
quality of life, event avoided)
Existing evidence The source of current evidence (e.g. meta-analysis, systematic 
review, clinical studies or expert opinion)
Effectiveness of the comparator/control The effectiveness of the comparator (e.g. baseline probability or 
mean estimate of the outcome of evaluated), with standard error 
or confidence interval
Relative effectiveness of the intervention The relative effectiveness of the intervention (e.g. relative risk or 
risk difference), with standard error or confidence interval
Cost of the comparator The expected cost of the comparator
Cost of the intervention The expected cost of the intervention or incremental cost
Willingness-to-pay Indicate the monetary value of one unit of effectiveness
Value of improved  
implementation
Current level of implementation/uptake The current level of implementation/uptake based on existing 
evidence
Expected level of implementation/uptake The expected level of implementation/uptake with the new 
research
Population benefiting from 
research findings
Annual incidence Incidence of the condition being researched
Prevalence Prevalence of the condition being researched
Durability of information Time in years over which the findings from the new research is 
useful
Other inputs Time to report research results Time in years for research results to report
Discount rate The rate of discounting future benefits and costs (e.g. 5%)
Direct research cost Research study budget including fixed and variable cost
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preventing surgical site infection in obese women undergo-
ing caesarean section. The calculations were performed in 
Microsoft  Excel® (Version 2013). Technical details of the 
calculations are provided in Appendix 1.
3.1  Nurse‑led Multimodal Intervention in Men 
with Advanced Prostate Cancer
Men with advanced prostate cancer have higher levels of 
psychological distress and poorer quality of life [37, 38]. 
Currently, there are no proven effective ways to improve psy-
chological adjustment and quality-of-life outcomes for men 
with this condition. A randomised controlled trial is pro-
posed to evaluate the effectiveness and cost-effectiveness of 
a tele-based nurse-led multimodal psychosocial intervention 
compared with usual care. The proposed study will have two 
arms: (1) minimally enhanced usual care (standard medical 
management with a package of patient education materials); 
and (2) nurse-led multimodal psychosocial care delivered 
over four weekly telephone sessions with a final booster fol-
low-up session 1 month subsequently. The study will include 
250 men (i.e., 125 in each arm) with advanced prostate can-
cer. The duration of the trial will be four years and the total 
requested budget is approximately $0.85 million.
Available evidence comes from a subgroup (n = 110) in 
a trial evaluating the cost and effectiveness of an individu-
alised cognitive behavioural intervention comprising five 
sessions of telephone-based counselling compared with a 
nurse-led single session of self-management in highly dis-
tressed cancer patients [39]. The intervention group had 
0.037 QALYs gained (95% CI − 0.045–0.118) with an incre-
mental cost of − $322 (95% CI − 2609–1964). At $50,000 
per QALY gained the incremental net monetary benefit was 
$2172 (95% CI − 2610–8551) [40]. The population expected 
to benefit from the results of the study is based on around 
32,000 patients, based on a prevalent population of 25,000 
patients with advanced prostate cancer together with 8% of 
newly diagnosed prostate cancer cases (17,000) progressing 
into advanced disease every year [41]. The research team 
expect an uptake rate from 10% in year one up to 50% in year 
five (average 30%, assuming 10% increment every year), if 
the expected benefits were confirmed in the proposed larger 
trial.
Simulating the expected benefit from a clinical trial of 
250 patients, the expected value of reducing uncertainty is 
$215 per patient (Appendix 1). The benefit from improved 
implementation is $650 (i.e., (30–0%) × $2172) per patient, 
and the expected value of research is around $865 per patient 
(i.e., $215 + $650). The expected value of research at the 
population level, over 5 years, is around $27.70 million 
(i.e., $865 × 32,000). With a research budget of $0.85 mil-
lion and an opportunity cost for patients in the control arm 
of $0.27 million (i.e., 125 × $2172), the total research cost is 
$1.12 million. Thus, the expected net monetary gain of the 
proposed clinical trial is around $26.60 million (i.e., $27.7 
million–$1.12 million), which is a return on investment of 
approximately 2370%.
3.2  Negative Pressure Wound Therapy in Obese 
Women Undergoing Caesarean Section
Obese women undergoing caesarean section are at increased 
risk of postoperative infection. NPWT may be useful to 
prevent closed surgical incision complications including 
surgical site infection (SSI); however, the evidence on its 
effectiveness in this population is limited. A randomised 
controlled trial has been proposed to assess the effect of 
NPWT on SSI in obese women undergoing elective caesar-
ean section. The trial will include 400 patients (200 in each 
arm) who will be randomised to the NPWT or the standard 
hydrocolloid dressing. Trial duration is 4 years and the total 
budget requested is approximately $2 million.
From available evidence, the baseline risk of SSI in the 
control group is 24% (SE = 24%), which is based on a pooled 
estimate from observational studies reporting SSI in obese 
women undergoing caesarean surgery [42–45]. The rela-
tive risk (RR) of SSI in the intervention is obtained from 
the combined results of two small trials (n = 173) at 0.73 
(95% CI 0.39–1.32) [46, 47]. The cost of the NPWT device 
is $175 and for the hydrocolloid dressing $7.50. The will-
ingness-to-pay threshold for an SSI event avoided is set at 
approximately $4000, based on the weighted average cost of 
SSI treatment and reduced quality of life, which is assumed 
to reflect the maximum amount of money the decision maker 
is willing to pay to avoid an SSI event [48]. The intervention 
is expected to be implemented after the end of the trial and 
to be used in practice for at least 5 years. The population 
expected to benefit is estimated at 20,000 annually, since 
obese women undergoing caesarean surgery represent 20% 
of the 100,000 caesarean sections performed every year 
in Australia, with a population of 90,000 (discounted over 
5 years) [48, 49]. Expert advice indicates that the current 
level of implementation of NPWT is 25% and that a posi-
tive RCT may increase uptake from 30% in year 1 to 70% by 
year 5 (average 50%, assuming 10% increment every year).
The net monetary benefit of NPWT compared with col-
loid dressing can be calculated as the difference between 
the SSI probabilities between the two arms times the will-
ingness-to-pay threshold per an SSI event avoided, minus 
the difference in cost between the two interventions. Based 
on existing evidence, the incremental net benefit is $90 
(i.e., 24% − (0.73 × 24%) × $4000–$167.50). Simulating the 
expected benefit from a clinical trial of 400 patients, the 
expected value of reducing uncertainty is $51 per patient. 
The expected value of improvement in implementation is 
$23 (i.e., (50% − 25%) × $90) per patient. Thus, the expected 
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value of research per patient is $74 (i.e., $51 + $23) and the 
expected value of research at the population level is around 
$6.6 million (i.e., $74 × 90,000). With a research budget of 
$2 million and an opportunity cost of research of $18,000 
(i.e., $90 × 200), the total research cost is $2.02 million. 
Thus, the expected net benefit of research is around $4.58 
million (i.e., $6.6 million–$2.02 million) and the expected 
return on investment is around 227%. Table 2 summarises 
the inputs and results of the expected value of research 
calculations.
4  Discussion
Prioritising research proposals for funding is essential to 
ensure that limited research budgets are allocated to high-
quality and cost-effective projects. We propose a compre-
hensive framework that considers both the merits of research 
(e.g. team capability, study feasibility) and its value for 
money to guide research funding decisions. Importantly, 
the framework allows for comparison of research proposals 
across different research topics. The framework is aligned 
with most of the current evaluation processes whereby 
applications are received, screened for eligibility and com-
pleteness, and assessed against pre-defined criteria before a 
final decision is made through discussion and deliberation 
among panel members. The value-for-money component is 
incorporated in a later stage in the evaluation process and 
can be efficiently using information provided in funding 
applications.
In the first two steps in the framework, competing propos-
als are assessed against a pre-defined set of criteria such as 
scientific rigour, team quality, and research feasibility. This 
transparent approach provides clarity about the assessment 
criteria, and allows for the incorporation of relevant and 
important research attributes from the perspective of vari-
ous stakeholders including patients, researchers and funders. 
Of note, considering the needs of stakeholders has been sug-
gested as an important step to reduce research wastage [50]. 
Considering value for money as an attribute alongside other 
Table 2  Expected value-of-research calculations for the nurse-led intervention in prostate cancer and NPWT in caesarean section
NPWT negative pressure wound therapy, QALY quality-adjusted life-years, SSI surgical site infection, RR relative risk, RCT randomised con-
trolled trial, CI confidence interval
Nurse-led intervention in prostate cancer NPWT in caesarean section
Inputs
 Primary outcome of the new clinical trial QALY RR of SSI
 Source and size of existing evidence RCT (110 patients) Pooled RCTs (173 patients)
 Effectiveness of the control 0.577 QALYs 24% baseline risk of SSI
 Relative effectiveness of the intervention 0.037 (95% CI − 0.045–0.118) 0.73 (95% CI 0.39–1.32)
 Willingness-to-pay $50,000/QALY $5000/SSI avoided
 Cost of the comparator $4095 $7.5 (assumed fixed)
 Cost/incremental cost of the intervention $ − 322 (95% CI − $2609–$1964) $175 (assumed fixed)
 Sample size of the new trial 250 400
 Current level of implementation/uptake 0% 25%
 Expected level of implementation/uptake 30% 50%
 Annual incidence 1300 20,000
 Prevalence 25,000 –
 Time to report research results 4 years 4 years
 Durability of information 5 years 5 years
 Research budget $850,000 $2000,000
 Discount rate 5% 5%
Outputs
 Expected value of reduced uncertainty/patient $215 $51
 Value of improved implementation/patient $650 $23
 Expected research value/patient $865 $74
 Expected research value/population $27,680,000 $6600,000
 Expected total research cost $1120,000 $2020,000
 Expected net benefit of research $26,560,000 $4580,000
 Return on investment 2370% 227%
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criteria (e.g. using MCDA) to calculate a composite score 
to rank proposals may not be ideal because it is burdensome 
to estimate value for money for all applications, and, impor-
tantly, it does not consider the opportunity cost forgone 
when applications that are not cost-effective are prioritised 
because they are deemed to be of high quality and/or feasi-
bility. This can be overcome by assigning monetary values 
to all attributes, but this task is challenging and may not 
be acceptable by stakeholders. For instance, what monetary 
value should be assigned to equity or innovation? Adding 
the value-for-money aspect to a separate and sequential stage 
of the evaluation process ascertains that only a shortlist of 
high-quality and feasibility applications are evaluated for 
value for money.
To quantify the value of research, the framework com-
bines both the value of reducing uncertainty (i.e., VOI) 
and value of research in improving implementation. VOI 
is a rigorous analytical approach that is gaining increasing 
attention to prioritise research studies and to link research to 
decision makers’ needs (e.g. the need for additional research 
to guide reimbursement decisions); however, the value of 
reducing decision uncertainty cannot be separated from the 
impact of strengthening evidence on improving implementa-
tion of research findings [18, 20, 22]. Our approach builds 
on the observations of other researchers about the relation-
ship between strength of evidence and implementation, 
and how ignoring the benefits of improved implementation 
could underestimate the expected value of research [18, 20, 
22]. This step will improve research value and reduce wast-
age by considering the expected benefit of the intervention 
compared with other alternatives, uncertainty in existing 
evidence, the potential of future implementation, and the 
burden of the disease when the expected value or research 
is scaled up to the population level. Moreover, this approach 
facilitates linking research funding to reimbursement deci-
sion needs (e.g. collecting evidence to inform funding deci-
sions of novel drugs) [51].
The biggest challenge for incorporating value for money 
in research prioritisation frameworks has been the complex-
ity and burden of analysis to estimate VOI [5, 6, 52]. In 
our framework, only shortlisted applications will be evalu-
ated for value for money, which will reduce the burden of 
this vital step. Moreover, the framework adopts the mini-
mal modelling approach to calculate value of information, 
which does not require sophisticated modelling [32, 33]. In 
the framework, applicants will be providing key inputs from 
existing evidence or expert opinion. These inputs can be 
verified at a step before value of research calculation (e.g. 
during the assessment of proposals in Steps 1 and 2). Value 
of research calculations can be done in a short time once 
the inputs are provided, which we have demonstrated in two 
real-world examples for actual research grant applications. 
Moreover, and to facilitate calculations, a tool can be pro-
grammed in a suitable software whereby relevant inputs are 
entered and the estimates are calculated in seconds [53, 54]. 
The tool will provide a common interface between funders 
and researchers, which will improve transparency and 
acceptability of the outcomes.
This work is the first step in a larger project to develop 
a research evaluation tool to enable research funding 
organisations and researchers to prospectively assess value 
for money of research projects. Three research organisa-
tions were involved in the development of this framework, 
namely, Menzies Health Institute Queensland, Cancer 
Council Queensland and the Prostate Cancer Foundation 
of Australia. The face validity of the framework has been 
validated by leading researchers at these organisations. The 
next step is to develop a programmable tool to calculate 
value of research and to test the tool on a larger number of 
proposals from other funding organisations to evaluate its 
feasibility and impact in practice. It is worth mentioning that 
the analytical approaches to calculate value for money have 
been focused on applied and evaluative research (e.g. clini-
cal trials and cohort studies); nevertheless, research funding 
covers a wide range of research programs including basic 
research, and, therefore, it would be useful to explore how 
value for money can be evaluated for a wider scope of pro-
grams. Although our framework takes an Australian health-
system perspective, we believe that this approach is gen-
eralizable to other jurisdictions where researcher-initiated 
proposals are prioritised and selected for funding. Even if 
cost-effectiveness of researched interventions is not required 
in certain jurisdictions, value of research can be still calcu-
lated using health measures (e.g. life-years gained) rather 
than net monetary benefit [55].
The minimal approach we use to calculate VOI has some 
limitations. Namely, the availability of the data required to 
conduct the analyses, the need to use intermediate outcomes 
and the need to establish an appropriate willingness-to-pay 
thresholds. Furthermore, this approach does not capture all 
the costs and benefits (parameters) and is most suitable when 
there is a comparator arm. To overcome these limitations, 
certain assumptions have to be made such as the usefulness 
of existing evidence for the minimal modelling approach 
and the expected future implementation of the intervention. 
These assumptions might introduce biases to the results and 
undermine research prioritisation recommendations. To 
mitigate this risk, the quality of evidence should be care-
fully assessed to ensure that only good quality and relevant 
evidence is used in the calculations. Additionally, and in 
the absence of empirical evidence, expert opinion should 
be elicited using transparent and structured approaches [56, 
57]. The robustness of the results to these assumptions can 
be tested in sensitivity analyses and presented to decision 
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maker. It should be noted that when the minimal modelling 
approach is feasible (e.g. pilot study reporting comprehen-
sive outcomes, or expert opinion to empirically characterize 
the relationship between the trial’s primary endpoint and a 
comprehensive measure of health outcomes), it allows VOI 
analyses to be undertaken for the purpose of research pri-
oritisation when the expertise to perform a full modelling 
approach is not available and/or when the results of a VOI 
analysis are required very quickly. Of note, VOI analyses 
based on full modelling may be considered by organisations 
interested in having more accurate estimates of research 
value for money (e.g. for research proposals asking for high 
budgets). This task can be outsourced to specialised research 
groups to undertake; however, expertise and time required 
to conduct VOI analyses based on full modelling should 
be carefully considered. Finally, there might be a concern 
that research studies targeting certain diseases and small 
but marginalised population may not be selected for fund-
ing based on their unfavourable cost-effectiveness figures. In 
this regard, it should be emphasised that cost-effectiveness 
should not be the only consideration for making research 
funding decisions. As indicated in the final step in our pro-
posed framework, the decision will be made through discus-
sion and deliberation among panel members where other 
important aspects (e.g. equity) are considered.
5  Conclusion
We have proposed a comprehensive framework that inte-
grates value for money into the existing research prioritisa-
tion processes for funding organisations. Considering value 
for money alongside other important criteria to inform 
research funding decisions is essential achieve efficient utili-
sation of research budgets and maximise returns on research 
investments.
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